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F18 FDG PET/CT scanAbstract Objective: Patients with differentiated thyroid carcinoma (DTC) have generally an
encouraging prognosis, however, some patients develop an increasing level of serum thyroglobulin
(Tg) without detection of a recurrent tumor using conventional imaging tools such as the iodine-131
whole-body scanning (I131 scan). The objective of our study was to evaluate the clinical signiﬁcance
of [F18]-FDG-PET/CT in detection of tumor recurrence or metastases, in comparison to conven-
tional imaging such as the I131 scan.
Patients and methods: Between January 2013 and June 2013, [18F]-FDG-PET/CT examination
was done for 12 DTC patients with elevated thyroglobulin levels and who did not show any path-
ological lesions when conventional imaging modalities were used. All involved patients had under-
gone total thyroidectomy, and who had been followed-up by whole body iodine scan [F18]-FDG
PET/CT data were evaluated for detecting recurrent DTC lesions in study patients and compared
with those of other radiological and/or cytological investigations.
Results: Five of 12 patients (41.6 %) showed pathological [F18]-FDG uptake in the absence of
abnormal uptake in whole body iodine scan.
Conclusion: [F18]-FDG-PET/CT affords a valuable diagnostic method in detection of recurrence
or metastasis in patients with DTC who are tumor-free on conventional imaging studies with high
Tg levels.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.
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Patients with differentiated thyroid carcinoma (DTC) have
favorable prognosis, however, recurrence is noted in up to
30% of such patients (1). In clinical practice, measurement
of serum thyroglobulin (Tg) and the I131 whole body scan
(WBS) are the mainstays of DTC patient evaluation after
treatment and during follow-up. Although the I131 scan
has high speciﬁcity, yet some of papillary and follicular thy-
roid carcinoma recurrences are not avid for I131 uptake (2).
Neck ultrasonography (US) may also be helpful in early
detection of small cervical metastases as the most common
site of recurrence is the cervical lymph nodes (3). However,
a diagnostic dilemma is posed by patients with increased lev-
els of Tg, in the absence of detection of recurrent cancer
using conventional imaging tools such as the iodine-131
whole-body scanning or neck US. The loss of the capacity
to concentrate iodine when Tg levels are elevated demands
the use of imaging tools other than the I131 scan (4). Posi-
tron emission tomography (PET) is an advanced diagnostic
imaging permitting anatomical tumor localization, the major
positron emission tomography (PET) tracer in use is ﬂuorine
18 (18F) ﬂuorodeoxyglucose (FDG), which targets glucose
metabolism in tumors. The biological target for FDG is
the accelerated rate of glycolysis intrinsic to the tumor pro-
cesses. PET has been used to accurately detect both iodine-
and non-iodine avid recurrence. Moreover [18F]-FDG-PET
is performed before considering repeated high-dose radioio-
dine (RI) treatment, this may render unnecessary RI, and
further optimal management such as surgery or irradiation
can be usefully indicated.
Although recurrent or metastatic DTC tumors grow
rather slowly, such tumors consume more glucose than does
normal tissue. Consequently, the use of [18F]-FDG-PET
has been suggested to be valuable in patients who are nega-
tive (in terms of tumor recurrence) on conventional imaging
but who show elevated Tg levels. The technique has been
used to detect both local DTC recurrence and distant metas-
tasis (5). This may increase the clinical application of such
imaging modality in thyroid cancer patients because detailed
anatomical information is obtained and iodine-positive tissue
can be located (4).
The aim of our study was to evaluate the utility of [18F]-
FDG-PET/CT in detection of recurrent DTC in patients with
increasing serum Tg levels who showed no pathological ﬁnding
upon conventional imaging modalities such as cervical US and
the I131 scan.
2. Materials and methods
Between Jan 2013 and June 2013, 12 patients with histolog-
ically proven DTC were enrolled in our study. All patients
had previously undergone total thyroidectomy and all
patients showed increasing pathological Tg levels (Tg >
9–10 ng/mL) after TSH stimulation (TSH> 30 mU/L).
However, neither tumor recurrence nor metastasis could be
detected in any patient by post-therapeutic I131 scan, neck
US, or chest radiography. Patients with obvious cervical
pathology in US or positive ﬁne-needle aspiration cytology
(FNAC) were excluded from the study.2.1. Study protocol
(1) Blood and urine samples were collected for routine
examination; to measure blood TSH, Tg, and anti-
Tg antibody levels; and to assess urine iodine excre-
tion after 4 weeks of levothyroxine withdrawal. All
patients had consumed a low-iodine diet for the prior
2 weeks, following written instructions and assisted by
a dietician.
(2) A I131 scan was obtained 72 h after administration of 2–
4 mCi of I131 using a Philips Bright view dual headed
scanner and patients with negative scan were asked to
perform a [18F]-FDG PET/CT.
(3) Patients fasted for at least 4 h before PET/CT exami-
nation, and were (intravenously) given 370 MBq
[18F]-FDG. All patients were instructed to rest com-
fortably for 60 min and to empty the bladder before
scanning. Whole-body PET/CT images were obtained
using a Ingenuity, TF PET/CT /Philips. Seven or eight
frames (3 min/frame) of emission PET data were
acquired in the two-dimensional mode after low dose
non-contrast CT scans had been performed from the
base of the skull to the mid thigh (tube rotation time
of 1 s per revolution; 120 kV; 60 mA; 7.5 mm per rota-
tion; and an acquisition time of 60.9 s for a scan
length of 867 mm). Attenuation corrected PET/CT
images were reviewed on a Philips workstation. All
images were independently interpreted by two experi-
enced physicians and screened for ‘‘overactive uptake’’
indicative of functioning thyroid tissue on I131 scan
and standardized uptake value (SUV) more than 3.2
is considered as hyper metabolic abnormalities on
PET/CT.
3. Results
Findings on [18F]-FDG-PET were compared with data
from diagnostic whole body I131 scans. Moreover, the data
were compared with those of radiological imaging (US,
CT, and MRI information), and/or those of cytological
investigation (FNAC), to conﬁrm (or otherwise) the ﬁnd-
ings of the I131 scans, and those of PET/CT (using
[18F]-FDG). For each patient, the presence or absence,
and number and localization of any recurrent lesions (if
present) were determined. PET/CT scans ﬁndings were
considered positive, if there is hypermetabolic uptake with
SUV max > 3.2.
The characteristics of the 12 patients included in our study
are showed in Table 1. The demographic distribution included
3 male patients (25%) and 9 female patients (75%).
Five of our 12 patients had areas of abnormal FDG
uptake inspite of negative whole body iodine scan, they were
classiﬁed based on the anatomical distribution of F18 FDG
metabolically active lesions into 3 patients had recurrent
hypermetabolic cervical lymphadenopathy, one patient had
hypermetabolic mediastinal lymphadeopathy with lung
metastases (Fig. 1) and one patient had hypermetabolic
peritoneal nodule only (Fig. 2).
Table 1 Patients characteristics and radiological ﬁndings.
Patients No. Sex Age Pervious RI dose (mCi) Tg (ng/mL) TSH I131 Other imaging modalities F18-FDG PETCT
1 M 60 80 22.4 89 Ve Ve +ve
2 F 35 100 11.1 55 Ve Ve Ve
3 F 41 75 19.2 60 Ve Ve Ve
4 F 22 87 30 31 Ve Ve +ve
5 M 27 88 16.2 48 Ve Ve Ve
6 F 39 77 10.9 98 Ve Ve Ve
7 F 49 120 21 90 Ve Ve Ve
8 M 51 89 63.3 78 Ve Ve +ve
9 F 32 90 70.1 63 Ve Ve +ve
10 F 70 105 17.1 56 Ve Ve Ve
11 F 44 100 44.2 130 Ve Ve Ve
12 F 59 100 91.5 100 Ve Ve +ve
Fig. 1 48 year old female patient presented with history of papillary thyroid cancer treated by subtotal thyroidectomy followed by
ablative dose of radioactive iodine (100 mCi); on follow up despite negative I131 whole body scan (A) for any residual, recurrent
functioning thyroid tissue or distant metastases, yet the Tg was remarkably elevated, PET (C) and PET/CT (D) revealed increased avidity
of 18F-FDG uptake at the right lung (arrow heads) not evident in corresponding conventional CT image (B).
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Fig. 2 A male patient 52 year old presented with history of papillary-follicular thyroid cancer treated by total thyroidectomy followed by
large dose radioactive iodine therapy; the thyroglobulin level showed progressively increased titer on follow up in spite of ve whole body
iodine scan (A) while PET/CT and PET showed distant metastases in the form of small hypermetabolic peritoneal deposit (arrow heads)
with SUV max measured 5.73 (B and C) not seen on conventional CT (D).
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These are the results of our study on the use of PET/CT using
[18F]-FDG to locate recurrent DTC lesions in patients with
elevated thyroglobulin levels with no pathological lesions de-
tected by conventional imaging modalities. Our study showed
that the use of [18F]-FDG-PET/CT revealed the complete ex-
tent of the disease and afforded precise anatomical localization
of recurrent lesions in 5 out of 12 patients (41.6%). Thus, per-
forming [18F]-FDG-PET/CT before high-dose RI treatment
was considered, would facilitate diagnostic accuracy and might
avoid unnecessary exposure of patients to radiation.
Empirical high-dose RI treatment may be indicated in pa-
tients with increased levels of Tg in the absence of pathological
lesions detected by conventional imaging tests (the I131 scan,
neck US, and/or chest radiography) followed by a post-treat-
ment I131 scan. However, repeated empirical treatment with
RI may unnecessarily expose patients to high levels of radia-
tion; this may be a particular problem in patients who show
no I131 uptake on the post-treatment scan (5). Therefore, an
advanced diagnostic imaging technique providing accurate
anatomical localization, such as [18F]-FDG-PET/CT, is re-
quired. The information provided by such scans is necessary
to allow physicians to accurately locate metastatic lesions
and to indicate the most efﬁcient therapeutic options.
In the past years, SUV max of 2.5 was considered by many
studies as a cut off value to differentiate benign and malignant
tumors, however, in countries where the incidence of infectious
and inﬂammatory disease is higher, this cut off value does not
work and a signiﬁcantly higher SUV is noted in infections and
inﬂammation (6).In our study, we used SUV max of 3.2 as a cut off value for
detecting malignancies as also recommended by Wong et al.
(7), who found that using this cut off value yielded a sensitivity
of 92% and speciﬁcity of 70% for recurrent head and neck
malignancies, similar cut off value is used by Takeda et al.
(8), who stated that SUV max of 3.2 showed sensitivity of
100% and sensitivity of 96% for detecting recurrence of local-
ized non small cell carcinomas. Huang et al. (9), showed that
the same SUV max is the cut off value to predict tumor control
of HCC after ablative radiotherapy, also Ergul et al. (10),
showed that cut off of 3.2 obtained the most effective sensitiv-
ity and speciﬁcity in the diagnosis of pancreatic cancer. While
Wafaie et al. (11), used SUV max of 3 as a cut off value for
detecting malignant osseous lesions, Meteser et al. (12), used
SUV max of 3.1 to detect malignant adrenal tumors, Choi
et al. (13) used SUV max of 3 as a cut off value for detecting
recurrence of papillary thyroid carcinoma.
In our patient series, PET/CT using [18F]-FDG was more
accurate in terms of lesion localization than was conventional
imaging in 5 of our 12 patients (41.6%). Currently, [18F]-
FDG-PET/CT is recognized as useful in examination of
DTC patients who present with negative I131 scan data but
pathologically increased Tg levels (5) Moreover, any difference
between PET ﬁndings and conventional I131 scan information
can provide important clinical clues relevant to treatment of
recurrent DTC.
Some authors have reported that TSH elevation increases
[18F]-FDG uptake in DTC patients experiencing recurrence
and seems to improve PET/CT scan sensitivity. In such pa-
tients, the value of hormonal stimulation by TSH is great as
small sized or low metabolic activity lesions become apparent
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(sensitivity) of scan data obtained after hormonal TSH stimu-
lation (15). Accordingly, no consensus on the effect of TSH
stimulation on FDG-PET accuracy has been attained and it
is important to render scanning cost-effective (5).
In clinical practice, RI treatment of patients with negative
low dose diagnostic I131 scan but with elevated Tg levels has
been used diagnostically, therapeutically, and assessment of
prognosis (16). In addition, patients who show no iodine accu-
mulation on post-treatment I131 scanning (which may indicate
tumor dedifferentiation) have a poorer prognosis than do oth-
ers (17).
Seven of our 12 patients showed no abnormality in PET/
CT although having high levels of increased thyroglobulin.
They were managed according to the American thyroid associ-
ation (18) which recommended that empiric radioactive iodine
therapy (100–200 mCi) might be considered in patients with
elevated thyroglobulin (thyroglobulin levels after T4 with-
drawal of 10 ng/ml or higher, or a level of 5 ng/ml after TSH
stimulation) or rising serum levels of thyroglobulin in whom
imaging failed to reveal a potential tumor source.
Our study had some limitations. Our patient number was
small and large prospective investigations are needed to sup-
port our data. Second our follow-up period was relatively
short and longer periods are needed to establish statistically
reliable data.
In conclusion [18F]-FDG PET/CT is a useful diagnostic
tool when recurrence occurs in DTC patients who have ele-
vated Tg levels but no deﬁnitive abnormalities by conventional
imaging.Conﬂict of interest
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